Premium
Glycoproteomics in neurodegenerative diseases
Author(s) -
Hwang Hyejin,
Zhang Jianpeng,
Chung Kathryn A.,
Leverenz James B.,
Zabetian Cyrus P.,
Peskind Elaine R.,
Jankovic Joseph,
Su Zhen,
Hancock Aneeka M.,
Pan Catherine,
Montine Thomas J.,
Pan Sheng,
Nutt John,
Albin Roger,
Gearing Marla,
Beyer Richard P.,
Shi Min,
Zhang Jing
Publication year - 2009
Publication title -
mass spectrometry reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 126
eISSN - 1098-2787
pISSN - 0277-7037
DOI - 10.1002/mas.20221
Subject(s) - glycoproteomics , neurodegeneration , glycoprotein , proteomics , biomarker , glycosylation , computational biology , chemistry , disease , biomarker discovery , neuroscience , glycan , biology , biochemistry , medicine , pathology , gene
Protein glycosylation regulates protein function and cellular distribution. Additionally, aberrant protein glycosylations have been recognized to play major roles in human disorders, including neurodegenerative diseases. Glycoproteomics, a branch of proteomics that catalogs and quantifies glycoproteins, provides a powerful means to systematically profile the glycopeptides or glycoproteins of a complex mixture that are highly enriched in body fluids, and therefore, carry great potential to be diagnostic and/or prognostic markers. Application of this mass spectrometry‐based technology to the study of neurodegenerative disorders (e.g., Alzheimer's disease and Parkinson's disease) is relatively new, and is expected to provide insight into the biochemical pathogenesis of neurodegeneration, as well as biomarker discovery. In this review, we have summarized the current understanding of glycoproteins in biology and neurodegenerative disease, and have discussed existing proteomic technologies that are utilized to characterize glycoproteins. Some of the ongoing studies, where glycoproteins isolated from cerebrospinal fluid and human brain are being characterized in Parkinson's disease at different stages versus controls, are presented, along with future applications of targeted validation of brain specific glycoproteins in body fluids. © 2009 Wiley Periodicals, Inc., Mass Spec Rev 29:79–125, 2010